Revalia Bio
PrivateLast Round
Grant
Dec 5, 2025
Total Funding Raised
$41.2M
Company Overview
Revalia Bio is a biotechnology company that operates a platform for 'Human Data Trials,' a new category of pre-clinical research. The company provides drug developers with early, predictive insights from real, functional human organs that are unsuitable for clinical transplant. By reviving and sustaining these organs with proprietary perfusion technology, Revalia enables biotech and pharmaceutical companies to evaluate new therapies for safety, efficacy, and mechanism of action before starting human clinical trials. This approach aims to address the high failure rate (over 90%) of drug candidates, which is often due to poor translation from animal models to human biology. A spinout from Yale University, the company has commercially launched and secured contracts with major pharmaceutical companies.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Biotech Equipment, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Revalia Bio Comps
Public and private peers based on sector, stage, and business model.
Revalia Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 5, 2025 | ||||
| Seed | Sep 4, 2025 |
Key People
Founding team and executive leadership
Revalia Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Seed |
| Sierra Ventures | Seed |
| America's Frontier Fund | Seed |
| Pamir Ventures | Seed |
| National Kidney Foundation Innovation Fund | Seed |
| BoxOne Ventures | Seed |
| ARPA-H | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Secured $30M in government contracts.
- Jan 1, 2026
Secured an ARPA-H award.
Revalia Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Revalia Bio's valuation, stock price, and market status.
